Related Experiment Video
Updated: Feb 1, 2026

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts
Published on: May 13, 2014
Inhibition of osteoblast differentiation by ritonavir
Yoshitaka Wakabayashi1, Yusuke Yoshino2, Kazunori Seo2
1Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Insights
Ritonavir, an anti-HIV protease inhibitor, was found to inhibit osteoblast differentiation in vitro. This finding may explain the link between protease inhibitor use and osteoporosis in HIV patients.
Area of Science:
- Biomedical Science
- Cell Biology
- Pharmacology
Background:
- Osteoporosis is a common complication in patients with human immunodeficiency virus (HIV).
- Antiretroviral drugs, particularly protease inhibitors, are suspected contributors to osteoporosis in HIV-infected individuals.
- The precise mechanisms by which anti-HIV drugs impact bone health remain incompletely understood.
Purpose of the Study:
- To investigate the effect of specific protease inhibitors on osteoblast differentiation in vitro.
- To determine if ritonavir, lopinavir, darunavir, or atazanavir inhibit the differentiation of osteoblastic cells.
Main Methods:
- MC3T3-E1 cells, a mouse osteoblastic cell line, were cultured in differentiation medium.
- Cells were treated with or without various protease inhibitors (ritonavir, lopinavir, darunavir, atazanavir).
- Alkaline phosphatase (ALP) activity and Runt-related transcription factor 2 (Runx2) expression were analyzed.
Main Results:
- Ritonavir significantly reduced ALP activity, indicating inhibition of osteoblast differentiation.
- No significant reduction in ALP activity was observed with lopinavir, darunavir, or atazanavir.
- Ritonavir also inhibited the early expression of Runx2, a critical transcription factor for osteoblast differentiation.
Conclusions:
- Ritonavir inhibits osteoblast differentiation in vitro, suggesting a potential mechanism for osteoporosis development in HIV patients on protease inhibitor therapy.
- This study provides the first in vitro evidence of ritonavir's inhibitory effect on osteoblast differentiation.
- Findings may elucidate the role of protease inhibitors in antiretroviral therapy-induced osteopenia.
Abstract:
Osteoporosis is one of the chronic complications seen in human immunodeficiency virus (HIV)-infected patients, and affects patients at high prevalence. The causes of osteoporosis in HIV-infected patients are multiple, and include chronic HIV infection, living habits such as smoking and alcohol consumption, and antiretroviral drug use. Among antiretroviral drugs, protease inhibitors have been reported to be associated with osteoporosis. However, it remains to be determined how anti-HIV drugs affect osteoblast differentiation. In the current study, MC3T3-E1 cells, a mouse osteoblastic cell line, were cultured in osteoblast differentiation medium with or without different protease inhibitors (ritonavir, lopinavir, darunavir or atazanavir), and alkaline phosphatase (ALP) activity and the expression of Runt-related transcription factor 2 (Runx2) were analyzed. The ALP activity in MC3T3-E1 cells cultured with ritonavir was significantly reduced compared with that in cells in only osteoblast inducer reagent, indicating that ritonavir inhibited osteoblast differentiation. Meanwhile, ALP activity was not reduced in cells cultured with any of the other inhibitors. In addition, ritonavir inhibited the expression of Runx2, a key regulator of osteoblast differentiation, in the early period of osteoblast differentiation. To the best of our knowledge, this is the first study to demonstrate that ritonavir inhibits osteoblast differentiation in vitro. The present findings may explain the mechanism of osteopenia induced by combination antiretroviral therapy involving protease inhibitors.
More Related Videos
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Inhibition of Cdk Activity
Implicit Differentiation
Logarithmic Differentiation
Cellular Differentiation
A zygote is a...

